"name","label","id","uuid:ID","description","instanceType","rationale"
"Study Design 1","","StudyDesign_1","69972606-0f10-439d-baf2-b0a2b10c19a5","The main design for the study","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
